Hetrombopag Added to Cyclosporine as the First‐Line Treatment for Patients With Non‐Severe Aplastic Anemia: A Phase 2 Multicenter Trial

Documenti analoghi

• Flu/Cy Plus PTCy Conditioning Regimen in Haplo‐ HSCT of Severe Aplastic Anemia
  di: Li Huang, et al.
  Pubblicazione: (2026)
• Comparison of Hetrombopag and Eltrombopag Added to First‐Line Immunosuppressive Therapy in Severe Aplastic Anemia
  di: Baohang Zhang, et al.
  Pubblicazione: (2025)
• A Case of Successful Allogeneic Hematopoietic Stem Cell Transplantation in a Severely Underweight Patient with Aplastic Anemia
  di: Lilija Banceviča, et al.
  Pubblicazione: (2024)
• Allogeneic HSCT in Aplastic Anemia: Current Evidence, Controversies, and Practical Decision‐Making
  di: Arjun Datt Law, et al.
  Pubblicazione: (2026)
• Absolute Immature Platelet Count: An Accessible Biomarker to Distinguish Aplastic Anemia and Immune Thrombocytopenia
  di: Michelle Zhu, et al.
  Pubblicazione: (2024)